BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, Grubmüller B, Gandaglia G, Briganti A, Karnes RJ. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. Eur Urol Oncol 2018;1:46-53. [PMID: 31100228 DOI: 10.1016/j.euo.2018.03.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Babst C, Amiel T, Maurer T, Knipper S, Lunger L, Tauber R, Retz M, Herkommer K, Eiber M, von Amsberg G, Graefen M, Gschwend J, Steuber T, Heck M. Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer. Asian Journal of Urology 2021. [DOI: 10.1016/j.ajur.2021.04.003] [Reference Citation Analysis]
2 McCormick BZ, Chery L, Chapin BF. Contemporary outcomes following robotic prostatectomy for locally advanced and metastatic prostate cancer. Transl Androl Urol 2021;10:2178-87. [PMID: 34159100 DOI: 10.21037/tau-20-1002] [Reference Citation Analysis]
3 Knipper S, Beyer B, Mandel P, Tennstedt P, Tilki D, Steuber T, Graefen M. Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H. World J Urol 2020;38:1459-64. [PMID: 31511970 DOI: 10.1007/s00345-019-02950-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
4 Mahjoub S, Heidenreich A. Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review. Transl Androl Urol 2021;10:3167-75. [PMID: 34430419 DOI: 10.21037/tau-20-1033] [Reference Citation Analysis]
5 Heidenreich A, Pfister D. Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease. Current Opinion in Urology 2020;30:90-7. [DOI: 10.1097/mou.0000000000000691] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Püllen L, Sprave T, Hadaschik B, Wiegel T. [Local and metastasis-directed therapy for oligometastatic prostate cancer]. Aktuelle Urol 2021;52:149-54. [PMID: 33561877 DOI: 10.1055/a-1328-9975] [Reference Citation Analysis]
7 Mokos I, El Saleh A, Kuliš T, Topalović Grković M, Bačak Kocman I, Kaštelan Ž. SURGICAL TREATMENT OF HIGH-RISK PROSTATIC CARCINOMA AND OLIGOMETASTATIC DISEASE. Acta Clin Croat 2019;58:21-3. [PMID: 34975194 DOI: 10.20471/acc.2019.58.s2.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Koie T, Hagiwara N, Yamada T, Kondo H, Ito H, Tomioka M, Kawashima K, Kato D, Iinuma K, Nakane K. Usefulness of robot-assisted radical prostatectomy in a patient with oligometastatic castration-resistant prostate cancer. IJU Case Rep 2021;4:26-8. [PMID: 33426491 DOI: 10.1002/iju5.12229] [Reference Citation Analysis]
9 Huebner N, Rasul S, Baltzer P, Clauser P, Hermann Grubmüller K, Mitterhauser M, Hacker M, Heidenreich A, Rajwa P, Fajkovic H, Shariat SF, Grubmüller B. Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery. European Urology Open Science 2022;40:117-24. [DOI: 10.1016/j.euros.2022.04.003] [Reference Citation Analysis]
10 Li Y, Wang N, Zhao D, Wang J, Jiang L, Wang Y, Chen D, Wu Z, Zhou F, Yang Z. Cytoreductive prostate cryoablation and metronomic cyclophosphamide for metastatic hormone-sensitive prostate cancer. Future Oncol 2022;18:2373-80. [PMID: 35440168 DOI: 10.2217/fon-2021-1424] [Reference Citation Analysis]
11 Heidenreich A. Novel therapies for advanced urologic cancers. Curr Opin Urol 2020;30:594-601. [PMID: 32453002 DOI: 10.1097/MOU.0000000000000775] [Reference Citation Analysis]
12 Buelens S, Poelaert F, Claeys T, De Bleser E, Dhondt B, Verla W, Ost P, Rappe B, De Troyer B, Verbaeys C, Kimpe B, Billiet I, Plancke H, Fransis K, Willemen P, Ameye F, Decaestecker K, Lumen N. Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU Int 2021. [PMID: 34289231 DOI: 10.1111/bju.15553] [Reference Citation Analysis]
13 Roy CSD, Sachdeva A, Kandaswamy GV, Rai BP. The role of surgery in high risk and advanced prostate cancer: A narrative review. Turk J Urol 2021;47:S56-64. [PMID: 33201799 DOI: 10.5152/tud.2020.20475] [Reference Citation Analysis]
14 Knipper S, Graefen M, Hadaschik B, Wiegel T. [Treatment concepts for primary oligometastatic prostate cancer]. Urologe A 2020;59:659-64. [PMID: 32274541 DOI: 10.1007/s00120-020-01186-w] [Reference Citation Analysis]
15 Connor MJ, Shah TT, Smigielska K, Day E, Sukumar J, Fiorentino F, Sarwar N, Gonzalez M, Falconer A, Klimowska-Nassar N, Evans M, Naismith OF, Thippu Jayaprakash K, Price D, Gayadeen S, Basak D, Horan G, McGrath J, Sheehan D, Kumar M, Ibrahim A, Brock C, Pearson RA, Anyamene N, Heath C, Shergill I, Rai B, Hellawell G, McCracken S, Khoubehi B, Mangar S, Khoo V, Dudderidge T, Staffurth JN, Winkler M, Ahmed HU. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. BMJ Open 2021;11:e042953. [PMID: 33632752 DOI: 10.1136/bmjopen-2020-042953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol 2021;18:79-92. [PMID: 33328650 DOI: 10.1038/s41585-020-00400-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
17 Xue P, Wu Z, Wang K, Gao G, Zhuang M, Yan M. Oncological Outcome of Combining Cytoreductive Prostatectomy and Metastasis-Directed Radiotherapy in Patients with Prostate Cancer and Bone Oligometastases: A Retrospective Cohort Study. Cancer Manag Res 2020;12:8867-73. [PMID: 33061582 DOI: 10.2147/CMAR.S270882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Falagario U, Veccia A, Weprin S, Albuquerque EV, Nahas WC, Carrieri G, Pansadoro V, Hampton LJ, Porpiglia F, Autorino R. Robotic-assisted surgery for the treatment of urologic cancers: recent advances. Expert Rev Med Devices 2020;17:579-90. [PMID: 32342705 DOI: 10.1080/17434440.2020.1762487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Robinsson D. Be gentle with ideas but harsh on facts. Scand J Urol 2022;:1. [PMID: 35289713 DOI: 10.1080/21681805.2022.2050805] [Reference Citation Analysis]
20 Weiner AB, Nettey OS, Morgans AK. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm. Curr Treat Options Oncol 2019;20:69. [PMID: 31286275 DOI: 10.1007/s11864-019-0668-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
21 Katayama S, Mori K, Pradere B, Mostafaei H, Schuettfort VM, Quhal F, Motlagh RS, Laukhtina E, Grossmann NC, Rajwa P, Aydh A, König F, Mathieu R, Nyirady P, Karakiewicz PI, Nasu Y, Shariat SF. Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. Scand J Urol 2022;:1-9. [PMID: 35142251 DOI: 10.1080/21681805.2022.2034941] [Reference Citation Analysis]
22 Juan GR, Laura FH, Javier PV, Natalia VC, Mᵃ Isabel GR, Enrique RG, José Luis SP, Pablo AL, Noelia SS, Roser VD, Jesús M. Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review. Cancers 2022;14:2017. [DOI: 10.3390/cancers14082017] [Reference Citation Analysis]
23 Lan T, Chen Y, Su Q, Ye J. Oncological Outcome of Cytoreductive Radical Prostatectomy in Prostate Cancer Patients With Bone Oligometastases. Urology 2019;131:166-75. [PMID: 31181273 DOI: 10.1016/j.urology.2019.03.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]